Slide 1: Exchange filing cover letter for investor presentation
January 23, 2026 To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS Dear Sir / Ma
Slide 2: Q3 & 9M-FY 2026 Financial Results
Q3 & 9M-FY 2026 Financial Results 23/01/2026 © 2025 Laurus Labs Ltd.
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. W
Slide 4: Agenda
Agenda 1 Q3 & 9M FY 2026 Corporate Overview 2 Q3 & 9M FY 2026 Financial Overview 3 Q3 & 9M FY 2026 Business Review & Strategy © 2025 Laurus Labs Ltd. Q3 & 9M - FY26 Results Presentation 23/01/2026 3
Slide 5: Corporate Overview
1 Corporate Overview Q3 & 9M FY 2026 4
Slide 6: Executive Summary
Executive Summary • Robust performance in 9M; ₹ 5,001 Cr Revenues with 30% growth • Strong momentum led by CDMO division supported by robust performance in Generics division • ₹ 1,303 Cr EBITDA resulted in a margin of 26.1%, increased by 9.4% pts, due to improving operational leverage • Delivered Gr
Slide 7: Other Q3 Material updates
Other Q3 Material updates • Healthy levels of progress across technologies and sites within CDMO business from existing long-term relationships • Gene therapy/antibody-drug conjugate Process development lab operationalized in Hyderabad and cGMP facility build on track • Increased capital in JV, KRKA
Slide 8: Advancing Key CAPEX projects, and investment into new modality
Advancing Key CAPEX projects, and investment into new modality • >85% in Growth CAPEX CAPEX Project Mix Phase-wise Split of CAPEX • Ongoing investments in Commercial scale Peptides manufacturing to support 12% 22% pipeline opportunities 30% ~ ₹ 3,900 Cr 1 • Client specific CMO oral dosage capacity T
Slide 9: Integrated 'D & M' platform & Expanding Capabilities to support Global customers
Integrated ‘D & M’ platform & Expanding Capabilities to support Global customers R&D center Small Molecules R&D with Kilo lab, Hyderabad Unit 1 & 3, Vizag 3600 KL DS/DP Development 1 API/DS Manufacturing 1 2 3 4 5 6 8,200 KL Reactors volumes New R&D, Hyderabad Unit 5, Vizag 161 KL DS Development 1 D
Slide 10: Financial Overview
2 Financial Overview Q3 & 9M FY 2026 9
Slide 11: 9M FY26: Sustained strong performance
9M FY26: Sustained strong performance 9M FY26 Financial Summary Comments [₹ Crore] 9M FY26 9M FY25 Y-o-Y • Revenues : ₹ 5,001 Cr, increased 30% driven by healthy growth across both CDMO and Generics division Revenues 5,001 3,834 30% • Gross Margins : 60.1%, increased by 430 bps on better divisional
Slide 12: 9M FY26: CDMO execution remain strong, supported by Generics growth
9M FY26: CDMO execution remain strong, supported by Generics growth 9M FY26 Divisional Revenue Performance 9M FY26 Divisional Mix [₹ Crore] 9M FY26 9M FY25 Y-o-Y CDMO 1,491 1,044 43% 31% 28% CDMO 30% Small molecules 1,372 913 50% / +3% over last year Bio 119 131 -9% Generics 70% / -3% over last year
Slide 13: 3Q FY26: Revenue and Profit achieved strong growth
3Q FY26: Revenue and Profit achieved strong growth 3Q FY26 Financial Summary Comments [₹ Crore] 2Q FY26 3Q FY26 3Q FY25 Y-o-Y Q-o-Q • Revenues : ₹ 1,778 Cr, increased 26% primarily driven by robust Generics growth (both FDF & API business) supported by sustained CDMO Revenues 1,653 1,778 1,415 26% 8
Slide 14: 3Q FY26: Strong Generic performance supported by CDMO segment
3Q FY26: Strong Generic performance supported by CDMO segment 3Q FY26 Divisional Revenue Performance 3Q FY26 Divisional Mix [₹ Crore] 2Q FY26 3Q FY26 3Q FY25 Y-o-Y Q-o-Q CDMO 518 451 448 1% -13% 23% CDMO 25% Small molecules 471 408 400 2% -13% 34% / -6% over last year Bio 47 43 48 -10% -9% Generics
Slide 15: Summary Quarter Performance: Sustained growth momentum
Summary Quarter Performance: Sustained growth momentum EBITDA & Gross Profit Margins Revenues [₹ Cr] 900 [₹ Cr] 59.4% 59.9% 60.9% GPM 56.9% 800 55.1% 55.2% 58.0% 54.5% 1,778 49.8% 700 1,720 1,653 48.0% 1,570 600 1,440 1,415 27.7% 27.3% 38.0% OPM 26.0% 500 1,224 24.8% 1,195 20.1% 18.0% 400 28.0% 300
Slide 16: Business Review & Strategy
3 Business Review & Strategy Q3 & 9M FY 2026 15
Slide 17: CDMO – Small molecules: Sustained demand across scale and technology
CDMO – Small molecules: Sustained demand across scale and technology Revenue Growth Comments [₹ Cr] Y-o-Y ▲ 2% • Healthy cumulative performance >50% driven by strong Q-o-Q ▼ 13% recurring business from existing relationships and growth +50% projects ramp up. Muted Q3 growth due to campaign timing 13
Slide 18: Bio – Muted but better demand visibility ahead
Bio – Muted but better demand visibility ahead Revenue Growth Comments [₹ Cr] Y-o-Y ▼ 10% • Good progress on larger Global accounts within AOF business with Q-o-Q ▼ 9% continuing customer interest for dedicated lines -9% 131 • Progressing discussion for longer term contracts, better visibility 119 i
Slide 19: Generics – Solid execution and Increasing capacities
Generics – Solid execution and Increasing capacities Revenue Growth Comments [₹ Cr] Y-o-Y ▲ 37% +26% • Both FDF and API division contributing to strong growth and Q-o-Q ▲ 17% 3510 further investing into capacity expansion 2790 • Higher ARV volumes and strong offtake in select molecules 1974 within d
Slide 20: Cell, Gene and Other Advanced modalities - Updates
Cell, Gene and Other Advanced modalities - Updates Cell therapy Gene therapy & ADC capabilities • NexCAR19: Sustained demand > 550 infusions as on Dec’25. • R&D lab operationalized for Process development (technologies BCMA targeted Ph-1 dosing ongoing for r/r Multiple Myeloma available at site incl
Slide 21: R&D platform: Promoting Sustainable technology and Capability extension
R&D platform : Promoting Sustainable technology and Capability extension Significant Updates • Sophisticated PD capabilities for Complex synthetic molecules >75 R&D project* supported in FY25 • Advanced Flow chemistry / Biocatalysis platform application for multiple MNCs. Executed ton-level project
Slide 22: Maintain the Global standard Quality systems
Maintain the Global standard Quality systems “One Quality Standard for all Markets” 1380+ Quality audits & Inspection Global Customers, Regulatory Last US FDA inspection Authorities since inception Key Key Regulatory # audits (since Date EIR Status Facilities Certifications inception) 54 Inspection
Slide 23: Outlook FY 2026 – Well on track to deliver healthy Operational growth
Outlook FY 2026 – Well on track to deliver healthy Operational growth • Strong Revenue delivery: Based on continued robust CDMO industry outlook, Clinical and Commercial business momentum and Ramp-up of Growth projects, and Generics growth supported by CMO opportunities, stable ARV business • Margin
Slide 24: Appendix
Appendix Pinus Labs
Slide 25: Earnings call details
Earnings call details Laurus Labs Results Conference Call to be held on Friday, 23 January 2026 at 5:00 PM IST Dial – In – Details Universal Dial-In +91 22 6280 1384 Click below to Express Join with India Local access Number +91 22 7115 8285 Diamond Pass Singapore +800 1012045 Click here to register
Slide 26: Additional Information
Additional Information Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral